Xia Wang

 
 
Email: wangxia20080210@yeah.net
 
Education Background  

2012 - 2017, Ph.D., Pharmacy, East China University of Science and Technology
2008 - 2012, B.E., Pharmaceutical Engineering, East China University of Science and Technology.

Research Scopes  
  1. Developed a collaborative filtering-based method for disease-specific drug-target interaction prediction;

  2. Systems biology study on arachidonic acid network;

  3. Genetic mutation mining and druggable targets idenfication by high-throughput sequencing data;

  4. Developed a web-accessible and interactive drug discovery platform;

  5. Discovery of selective epidermal growth factor receptor (EGFR) inhibitors against L858R/T790M resistance mutation.

 
Publication  
  1. Xia Wang, Yihang Shen, Shiwei Wang, Shiliang Li, Weilin Zhang, Xiaofeng Liu, Luhua Lai, Jianfeng Pei, Honglin Li. PharmMapper 2017 update: a web server for potential drug target identification with a comprehensive target pharmacophore database. Nucleic Acids Res.2017.

  2. Chao Lv, Xueting Wu, Xia Wang, Juan Su, Huawu Zeng, Jing Zhao, Shan Lin, Runhui Liu, Honglin Li, Xuan Li, Weidong Zhang. The gene expression profiles in response to 102 traditional Chinese medicine (TCM) components: a general template for research on TCMs. Sci. Rep.2017. 7 : 352.       

  3. Xia Wang, Chenxu Pan, Jiayu Gong, Xiaofeng Liu, Honglin Li. Enhancing the Enrichment of Pharmacophore-Based Target Prediction for the Polypharmacological Profiles of Drugs. J. Chem. Inf. Model.2016. 56 : 1175-1183.

  4. Yongjia Hao#, Xia Wang#, Tao Zhang#, Deheng Sun, Yi Tong, Yuqiong Xu, Haiyang Chen, Linjiang Tong, Lili Zhu, Zhenjiang Zhao, Zhuo Chen, Jian Ding, Hua Xie, Yufang Xu, Honglin Li. Discovery and Structural Optimization of N5-Substituted 6,7-dioxo-6,7-dihydropteridines as Potent and Selective Epidermal Growth Factor Receptor (EGFR) Inhibitors Against L858R/T790M Resistance Mutation . J. Med. Chem.2016. 59 : 7111-7124.

  5. Qiao Li, Lina Quan, Jiankun Lyu, Zenghui He, Xia Wang, Jiajia Meng, Zhenjiang Zhao, Lili Zhu, Xiaofeng Liu, Honglin Li. Discovery of peptide inhibitors targeting human programmed death 1 (PD-1) receptor. Oncotarget, 2016. 7 : 64967-64976.

  6. Meijian Sun, Xia Wang, Chuanxin Zou, Zenghui He, Wei Liu, Honglin Li. Accurate prediction of RNA-binding protein residues with two discriminative structural descriptors. BMC Bioinformatics2016. 17 : 231.

  7. Zhonghua Gao, Yiming Shi, Zhe Qiang, Xia Wang, Shanzhai Shang, Yan Yang, Baowen Du, Huipan Peng, Xu Ji, Honglin Li, Fei Wang, Weilie Xiao. Plasiatine, an Unprecedented Indole–Phenylpropanoid Hybrid from Plantago asiatica as a Potent Activator of the Nonreceptor Protein Tyrosine Phosphatase Shp2. Sci. Rep.2016. 6 : 24945.

  8. Xia Wang, Haipeng Chen, Feng Yang, Jiayu Gong, Shiliang Li, Jianfeng Pei, Xiaofeng Liu, Hualiang Jiang, Luhua Lai, Honglin Li. iDrug: a web-accessible and interactive drug discovery and design platform. J. Cheminform.2014. 6 : 28.  

  9. Shoude Zhang, Lei Shan, Qiao Li, Xia Wang, Shiliang Li, Yuan Zhang, Jianjun Fu, Xiaofeng Liu, Honglin Li, Weidong Zhang*. Systematic Analysis of the Multiple Bioactivities of Green Tea through a Network Pharmacology Approach. Evid. Based Complement. Alternat. Med., 2014. 2014 : 512081.                              

User Login


Database


PTID

Contact us


Honglin Li's Lab
Shanghai Key Laboratory of New Drug Design
School of Pharmacy
East China University of Sci. & Tech.
Room 527, Building 18, 130 Meilong Road,
Shanghai, 200237, P. R. China
Tel: (86) 21 6425 0213
Prof. Honglin Li
hlli@ecust.edu.cn

Copyright © 2023 Prof. HongLin Li's Group, School of Pharmacy, East China University of Science & Technology · All Right Reserved.
沪ICP备19004698号-1 |  沪公网安备31011302004713号